Results for tag: "Secukinumab"

Secukinumab is a human monoclonal antibody used to treat immune disorders. It is used to treat moderate to severe plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis. It works by blocking the action of interleukin-17A, a protein that plays a role in inflammation. Secukinumab is administered as an injection under the skin. Secukinumab is a relatively new drug, having been approved by the US Food and Drug Administration in 2015. It is a biologic drug, meaning it is made from living cells, and is used to treat autoimmune diseases. It is generally well-tolerated, with the most common side effects being upper respiratory tract infections, headache, and injection site reactions. Secukinumab is marketed by Novartis, Amgen, and Pfizer. Novartis markets the drug under the brand name Cosentyx, while Amgen markets it under the brand name Ilumya. Pfizer markets the drug under the brand name Taltz. Show Less Read more